non-small cell lung cancer

AZ’s Imfinzi approved in early lung cancer in China
AZ’s Imfinzi approved in early lung cancer in China
Pharmaforum
China
AstraZeneca
Imfinizi
non-small cell lung cancer
Flag link:
Merck's Keytruda lung cancer sales may face new pressure, but investors shouldn't sweat it: analyst
Merck's Keytruda lung cancer sales may face new pressure, but investors shouldn't sweat it: analyst
Fierce Pharma
Merck
Keytruda
non-small cell lung cancer
Flag link:
AstraZeneca, on BMS' heels, scores lung cancer win with Imfinzi combos
AstraZeneca, on BMS' heels, scores lung cancer win with Imfinzi combos
Fierce Pharma
AstraZeneca
Imfinizi
non-small cell lung cancer
Flag link:
Bristol-Myers makes Opdivo pitch for frontline lung cancer with open label PhIII study
Bristol-Myers makes Opdivo pitch for frontline lung cancer with open label PhIII study
Endpoints
Bristol-Myers Squibb
Opdivo
non-small cell lung cancer
advanced non-small cell lung cancer
clinical trials
Flag link:
Merck’s KEYTRUDA approved as monotherapy in China for first-line treatment of certain patients with advanced NSCLC
Merck’s KEYTRUDA approved as monotherapy in China for first-line treatment of certain patients with advanced NSCLC
Pharmaceutical Business Review
Merck
Keytruda
China
non-small cell lung cancer
Flag link:
Samsung Bioepis announces phase 3 results of SB8, Bevacizumab biosimilar candidate, at ESMO 2019 Congress
Samsung Bioepis announces phase 3 results of SB8, Bevacizumab biosimilar candidate, at ESMO 2019 Congress
Pharmaceutical Business Review
ESMO
Samsung Bioepis
clinical trials
SB8
biosimilars
bevacizumab
non-small cell lung cancer
Flag link:
OncoCyte Acquires Razor Genomics to Improve Management of Early-Stage Lung Cancer
OncoCyte Acquires Razor Genomics to Improve Management of Early-Stage Lung Cancer
BioSpace
OncoCyte
Razor Genomics
diagnostics
M&A
non-small cell lung cancer
Flag link:
Roche’s Tecentriq monotherapy significantly improves OS in phase III lung cancer study
Roche’s Tecentriq monotherapy significantly improves OS in phase III lung cancer study
Pharmaceutical Business Review
Roche
Tecentriq
clinical trials
non-small cell lung cancer
Flag link:
Merck KGaA nabs FDA “Breakthrough” tag for MET-targeting lung cancer drug
Merck KGaA nabs FDA “Breakthrough” tag for MET-targeting lung cancer drug
Pharmaforum
FDA
Merck KGaA
MET
lung cancer
tepotinib
non-small cell lung cancer
Flag link:
WCLC: Merck's Keytruda dispels 'urban legend' with latest lung cancer survival win
WCLC: Merck's Keytruda dispels 'urban legend' with latest lung cancer survival win
Fierce Pharma
Merck
Keytruda
non-small cell lung cancer
WCLC
Flag link:
Lilly's RET drug, nabbed in Loxo buyout, hits 68% ORR in lung cancer
Lilly's RET drug, nabbed in Loxo buyout, hits 68% ORR in lung cancer
Fierce Biotech
Eli Lilly
Loxo Oncology
LOXO-292
non-small cell lung cancer
Flag link:
Novartis’ lung cancer drug edges closer to market after FDA grants fast review
Novartis’ lung cancer drug edges closer to market after FDA grants fast review
Pharmaforum
Novartis
Incyte
FDA
breakthrough therapy
non-small cell lung cancer
Flag link:
AZ gets China nod for Tagrisso in first-line lung cancer
AZ gets China nod for Tagrisso in first-line lung cancer
Pharmaforum
AstraZeneca
China
Tagrisso
non-small cell lung cancer
Flag link:
Amgen’s ‘White Whale’ Cancer Data May Send Shares to Record High
Amgen’s ‘White Whale’ Cancer Data May Send Shares to Record High
Bloomberg
Amgen
AMG 510
colon cancer
non-small cell lung cancer
Flag link:
Roche scores double cancer approval for new Bayer rival Rozlytrek
Roche scores double cancer approval for new Bayer rival Rozlytrek
Fierce Pharma
Roche
Rozlytrek
FDA
NTRK fusion-positive tumors
non-small cell lung cancer
Flag link:
MSD’s Keytruda plus chemo backed by NICE for lung cancer
MSD’s Keytruda plus chemo backed by NICE for lung cancer
Pharmaforum
Merck
Keytruda
NICE
non-small cell lung cancer
Flag link:
#ASCO19: MET inhibitors from Incyte/Novartis and Germany's Merck face off for rare subset of NSCLC patients
#ASCO19: MET inhibitors from Incyte/Novartis and Germany's Merck face off for rare subset of NSCLC patients
Endpoints
Novartis
ASCO 2019
Incyte
MET inhibitors
capmatinib
non-small cell lung cancer
Flag link:
ASCO: Death in Turning Point NSCLC trial overshadows 82% ORR
ASCO: Death in Turning Point NSCLC trial overshadows 82% ORR
Fierce Biotech
ASCO 2019
clinical trials
Turning Point Therapeutics
repotrectinib
non-small cell lung cancer
Flag link:
Imfinzi demonstrates overall survival at three years in unresectable stage III NSCLC
Imfinzi demonstrates overall survival at three years in unresectable stage III NSCLC
Pharmaceutical Business Review
AstraZeneca
Imfinzi
ASCO 2019
non-small cell lung cancer
Flag link:
Turning Point sinks on ASCO update for repotrectinib
Turning Point sinks on ASCO update for repotrectinib
BioCentury
ASCO 2019
Turning Point Therapeutics
repotrectinib
non-small cell lung cancer
Flag link:

Pages